What Do We Actually Know About Kids on Weight-Loss Drugs?
GLP-1 drugs like semaglutide (Ozempic and Wegovy) and tirzepatide (Mounjaro and Zepbound) have greatly changed the treatment of obesity and type 2 diabetes for the better. Plenty of adults in the U.S. have taken or are currently taking a GLP-1. Between 2019 and 2026, the researchers found, 0.6% of children ages 8 to 11 with obesity but without diabetes had been prescribed an off-label GLP-1, while the annual percentage of such children prescribed a GLP-1 dramatically increased year after year.
- ▪GLP-1 drugs like semaglutide (Ozempic and Wegovy) and tirzepatide (Mounjaro and Zepbound) have greatly changed the treatment of obesity and type 2 diabetes for the better.
- ▪Plenty of adults in the U.S. have taken or are currently taking a GLP-1.
- ▪Between 2019 and 2026, the researchers found, 0.6% of children ages 8 to 11 with obesity but without diabetes had been prescribed an off-label GLP-1, while the annual percentage of such children prescribed a GLP-1 dramatically increased yea
Gizmodo files mainly under tech. We currently carry 955 of its stories.
Story provenance
Source · retrieval · rights · ranking — open for full record
inspect →
Story provenance
Attribution is not the same as permission. This drawer separates discovery metadata, excerpts, WeSearch-generated summaries, reuse status, and whether the publisher receives the visit. Nothing here claims a legal grant the publisher has not made.
Record
| Original publisher | Gizmodo |
| Canonical URL | https://gizmodo.com/what-do-we-actually-know-about-kids-on-weight-loss-drugs-2000810701 |
| Publication time | Sat, 12 Sep 2026 11:30:01 +0000 |
| Retrieval time | 2026-09-12T11:32:50.737Z |
| Last seen | 2026-09-12T11:32:50.737Z |
| Headline source | Publisher (no WeSearch rewrite) |
| Excerpt source | publisher body |
| Excerpt method | First ~120 words (~800 chars) of extracted publisher body, fair-use limited. |
| Summary | WeSearch · cerebras-chat (WeSearch summarizer) |
| Summary source text | contentText |
| Citation coverage | Summary is a WeSearch-generated derivative; primary citation is the original publisher URL. |
| Cluster | x2Sh4gCvhS1P · 1 stories |
| Cluster logic | Grouped by semantic title/content similarity across sources within a rolling window. Same-publisher template collisions are excluded from coverage comparison. |
| Ranking reason | Story pages are not engagement-ranked. Hub feeds use recency, with optional source-diversified chronological ordering (cap consecutive stories per source). No personalized ranking. |
| Publisher visit | Yes — open original |
| Substitutes article? | No — link-out required for full text |
Rights status (four layers)
WeSearch handling by dimension
| Indexing | May the item be indexed (stored, ranked, made findable)? | Allowed |
| Snippet | May a short excerpt of the publisher's text be shown? | Allowed |
| AI summary | May WeSearch generate its own short summary of the article? | Limited |
| Retrieval / RAG | May the content be exposed for third-party retrieval-augmented generation? | Not asserted |
| Model training | May the content be used to train AI models? | Not asserted |
| Commercial reuse | May the content be reused commercially? | Not permitted |
Basis: Derived from the published RSS/Atom feed. Contact: [email protected]. Reviewed: 2026-07-24.
Opening excerpt (first ~120 words) tap to expand
GLP-1 drugs like semaglutide (Ozempic and Wegovy) and tirzepatide (Mounjaro and Zepbound) have greatly changed the treatment of obesity and type 2 diabetes for the better. Plenty of adults in the U.S. have taken or are currently taking a GLP-1. And increasingly, so are teens and young children, too.cnx.cmd.push(function(){cnx({"playerId":"92b7b46b-43ed-4e0e-b21b-2c999302d9d7","settings":{"advertising":{"macros":{"AD_UNIT":"/23178111854/od.gizmodo.com/article","CHILD_UNIT":"article","POST_ID":"2000810701","POST_TYPE":"post","CHANNEL":"science","SECTION":"health","SUBSECTION":"","CATEGORIES":"health","TAGS":"childrens-health,giz-asks,obesity","NOP":"0"},"timeBeforeFirstAd":0}}}).render("cnx-player-main")}); A study last week, for instance, concluded that while GLP-1 use overall remains rare…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Gizmodo.
Discussion
0 commentsMore from Gizmodo
